AI technology and longevity research drive interest in life extension

Artificial intelligence and biotechnology are driving a renewed interest in human longevity and life extension. Leaders in the AI sector, including Anthropic CEO Dario Amodei and OpenAI CEO Sam Altman, have expressed interest in the field, with Altman investing over $180 million in Retro Biosciences to extend healthy human life.

In London, longevity clinics like HUM 2 N offer expensive treatments such as cryotherapy, hyperbaric oxygen therapy, and NAD+ intravenous drips to a clientele ranging from athletes to elderly patients. This growing interest coincides with global demographic shifts, as aging populations increase in OECD countries.

Simultaneously, the use of AI for personal health inquiries is rising. Research indicates that 64% of patients use AI tools daily, with nearly half of those users seeking health-related information. While medical experts suggest AI can be useful for simplifying medical terms or organizing questions for doctors, they warn against using these tools for self-diagnosis or treatment decisions due to concerns regarding reliability and bias.